LU93081I2 - Ambrisentan utilisé en traitement combiné avec tadalafil - Google Patents

Ambrisentan utilisé en traitement combiné avec tadalafil Download PDF

Info

Publication number: LU93081I2
Authority: LU; Luxembourg
Prior art keywords: ambrisentan; tadalafil; treatment combined; treatment; combined
Prior art date: 2006-12-12

Application number

LU93081C

Other languages

English (en)

Original Assignee

Gilead Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-12-12

Filing date

2016-05-20

Publication date

2016-07-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39092031&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU93081(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-05-20 Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc

2016-07-20 Publication of LU93081I2 publication Critical patent/LU93081I2/fr

Links

OUJTZYPIHDYQMC-LJQANCHMSA-N ambrisentan Chemical compound O([C@@H](C(OC)(C=1C=CC=CC=1)C=1C=CC=CC=1)C(O)=O)C1=NC(C)=CC(C)=N1 OUJTZYPIHDYQMC-LJQANCHMSA-N 0.000 title 1
229960002414 ambrisentan Drugs 0.000 title 1
IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 title 1
229960000835 tadalafil Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

LU93081C 2006-12-12 2016-05-20 Ambrisentan utilisé en traitement combiné avec tadalafil LU93081I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US86966706P	2006-12-12	2006-12-12
PCT/US2007/087058 WO2008073928A1 (fr)	2006-12-12	2007-12-11	Composition de traitement de l'hypertension pulmonaire

Publications (1)

Publication Number	Publication Date
LU93081I2 true LU93081I2 (fr)	2016-07-20

Family

ID=39092031

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU93081C LU93081I2 (fr)	2006-12-12	2016-05-20	Ambrisentan utilisé en traitement combiné avec tadalafil

Country Status (15)

Country	Link
US (7)	US20080139593A1 (fr)
EP (2)	EP2952193A1 (fr)
JP (1)	JP2010512414A (fr)
AU (1)	AU2007333115B2 (fr)
CA (1)	CA2669536C (fr)
CY (1)	CY2016017I2 (fr)
DK (1)	DK2101777T3 (fr)
ES (1)	ES2544724T3 (fr)
HK (1)	HK1218393A1 (fr)
HU (2)	HUE025355T2 (fr)
LU (1)	LU93081I2 (fr)
PL (1)	PL2101777T3 (fr)
PT (1)	PT2101777E (fr)
SI (1)	SI2101777T1 (fr)
WO (1)	WO2008073928A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2101777T3 (pl)	2006-12-12	2015-10-30	Gilead Sciences Inc	Kompozycja do leczenia nadciśnienia płucnego
KR20100046189A (ko)	2007-07-11	2010-05-06	렉시컨 파마슈티컬스 인코퍼레이티드	폐고혈압 및 관련 질환 및 장애의 치료를 위한 방법 및 조성물
JP2010535210A (ja)	2007-07-31	2010-11-18	ギリード・コロラド・インコーポレーテッド	アンブリセンタンの代謝産物および誘導体
WO2010062640A1 (fr) *	2008-10-28	2010-06-03	Gilead Colorado, Inc.	Procédés de traitement d'une fibrose pulmonaire idiopathique et de complications associées
BR112012032766A2 (pt) *	2010-06-30	2019-09-24	Gilead Sciences Inc	uso de antagonistas do receptor de adenosina a2b para o tratamento da hipertensão pulmonar
DK2637664T3 (en) *	2010-10-15	2017-06-19	Gilead Sciences Inc	COMPOSITIONS AND METHODS FOR TREATMENT OF PULMONAL HYPERTENSION
WO2013024022A1 (fr) *	2011-08-12	2013-02-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Méthodes et compositions pharmaceutiques pour traiter l'hypertension pulmonaire
US20130225595A1 (en) *	2012-02-29	2013-08-29	Gilead Sciences, Inc.	Method for treating pulmonary arterial hypertension in a patient not having idiopathic pulmonary fibrosis
US20130224306A1 (en) *	2012-02-29	2013-08-29	Gilead Sciences, Inc.	Method for treating a pulmonary hypertension condition without companion diagnosis
WO2014003678A1 (fr) *	2012-06-28	2014-01-03	Xspray Microparticles Ab	Compositions pharmaceutiques comprenant de l'ambrisentan et des particules de dispersion solide contenant du tadalafil
US10518112B2 (en) *	2014-06-18	2019-12-31	Sonivie Ltd.	Method for treating secondary pulmonary hypertension
US10576083B2 (en) *	2015-08-13	2020-03-03	Cipla (UK) Limited	Method of treating pulmonary arterial hypertension
CN116531490A (zh)	2016-07-15	2023-08-04	阿塞勒隆制药公司	用于治疗肺高血压的组合物和方法
EP3675840A4 (fr) *	2017-08-30	2021-05-12	Bellerophon Pulse Technologies LLC	Utilisation d'oxyde nitrique inhalé pour l'amélioration de la fonction ventriculaire droite et/ou gauche
US20200360425A1 (en) *	2017-12-28	2020-11-19	Bellerophon Pulse Technologies Llc	Use Of Inhaled Nitric Oxide And Oxygen For The Treatment Of Pulmonary Hypertension
JP2022532076A (ja) *	2019-05-06	2022-07-13	アクテリオンファーマシューティカルズリミテッド	サルコイドーシス関連肺高血圧症の治療方法
CA3161960A1 (fr)	2019-12-16	2021-06-24	Tenax Therapeutics, Inc.	Levosimendan pour traiter l'hypertension pulmonaire accompagnee d'une insuffisance cardiaque au moyen d'une fraction d'ejection preservee (ph-hfpef)
RU2729033C1 (ru) *	2020-02-03	2020-08-03	Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр кардиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ кардиологии" Минздрава России)	Способ прогнозирования эффективности длительной специфической терапии у пациентов с идиопатической легочной гипертензией и неоперабельной хронической тромбоэмболической легочной гипертензией
EP4142731A1 (fr) *	2020-04-28	2023-03-08	Noorik Biopharmaceuticals AG	Traitement de complications pulmonaires d'infections à coronavirus
EP4142769A4 (fr)	2020-04-28	2024-05-15	Acceleron Pharma Inc.	Protéines actrii et leur utilisation dans le traitement de l'hypertension pulmonaire post-capillaire
EP3906928A1 (fr) *	2020-05-06	2021-11-10	Noorik Biopharmaceuticals AG	Traitement des complications pulmonaires du coronavirus
CN114324900A (zh) *	2021-12-03	2022-04-12	上海市肺科医院	一种促卵泡激素的应用
WO2023130028A1 (fr)	2021-12-31	2023-07-06	Tenax Therapeutics, Inc.	Formulations orales de levosimendan pour le traitement de l'hypertension pulmonaire avec insuffisance cardiaque à fraction d'éjection préservée
EP4648761A1 (fr) *	2023-01-09	2025-11-19	scPharmaceuticals Inc.	Méthodes de traitement utilisant des diurétiques de l'anse de henle
EP4684777A1 (fr)	2024-07-24	2026-01-28	Adalvo Limited	Composition pharmaceutique à dose fixe comprenant de l'acide (2s)-2--[(4,6-diméthylpyrimidin-2-yl)oxy -3-méthoxy-3,3-diphénylpropanoïque

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US4325525A (en)	1980-11-13	1982-04-20	General Motors Corporation	Mounting member
US5364620A (en)	1983-12-22	1994-11-15	Elan Corporation, Plc	Controlled absorption diltiazem formulation for once daily administration
US4902514A (en)	1988-07-21	1990-02-20	Alza Corporation	Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5250534A (en)	1990-06-20	1993-10-05	Pfizer Inc.	Pyrazolopyrimidinone antianginal agents
DE4313412A1 (de)	1993-04-23	1994-10-27	Basf Ag	3-(Het)aryl-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung
GB9401090D0 (en)	1994-01-21	1994-03-16	Glaxo Lab Sa	Chemical compounds
DE19533023B4 (de)	1994-10-14	2007-05-16	Basf Ag	Neue Carbonsäurederivate, ihre Herstellung und Verwendung
TR200001338T2 (tr)	1997-11-12	2000-08-21	Bayer Aktiengesellschaft	2-Fenil-ikameli imidazotriazinonlar
US6821975B1 (en)	1999-08-03	2004-11-23	Lilly Icos Llc	Beta-carboline drug products
CA2572179A1 (fr) *	2004-06-23	2006-01-19	Myogen, Inc.	Formulations d'enoximone et utilisation dans le traitement de maladies a mediation par pde-iii
US20060205733A1 (en) *	2004-08-26	2006-09-14	Encysive Pharmaceuticals	Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
CN101072564A (zh)	2004-08-26	2007-11-14	恩希赛弗制药公司	内皮缩血管肽a受体(eta)拮抗剂与磷酸二酯酶5(pde5)抑制剂的联合及其用途
EP1846411A4 (fr)	2005-01-25	2010-08-04	Glaxo Group Ltd	Agents antibacteriens
NZ571540A (en) *	2006-04-21	2010-10-29	Pfizer Prod Inc	Pyridine[3,4-b]pyrazinones for inhibiting PDE-5
PL2101777T3 (pl) *	2006-12-12	2015-10-30	Gilead Sciences Inc	Kompozycja do leczenia nadciśnienia płucnego
CA2669535A1 (fr) *	2006-12-12	2008-06-19	Gilead Colorado, Inc.	Utilisation de l'ambrisentan associe avec un inhibiteur de renine dans les troubles de l'hypertension
JP2010535210A (ja)	2007-07-31	2010-11-18	ギリード・コロラド・インコーポレーテッド	アンブリセンタンの代謝産物および誘導体
WO2010062640A1 (fr)	2008-10-28	2010-06-03	Gilead Colorado, Inc.	Procédés de traitement d'une fibrose pulmonaire idiopathique et de complications associées
DK2637664T3 (en)	2010-10-15	2017-06-19	Gilead Sciences Inc	COMPOSITIONS AND METHODS FOR TREATMENT OF PULMONAL HYPERTENSION

2007
- 2007-12-11 PL PL07855065T patent/PL2101777T3/pl unknown
- 2007-12-11 JP JP2009541511A patent/JP2010512414A/ja not_active Withdrawn
- 2007-12-11 DK DK07855065.4T patent/DK2101777T3/en active
- 2007-12-11 PT PT78550654T patent/PT2101777E/pt unknown
- 2007-12-11 EP EP15168201.0A patent/EP2952193A1/fr not_active Withdrawn
- 2007-12-11 AU AU2007333115A patent/AU2007333115B2/en active Active
- 2007-12-11 CA CA2669536A patent/CA2669536C/fr active Active
- 2007-12-11 US US11/953,955 patent/US20080139593A1/en not_active Abandoned
- 2007-12-11 ES ES07855065.4T patent/ES2544724T3/es active Active
- 2007-12-11 WO PCT/US2007/087058 patent/WO2008073928A1/fr not_active Ceased
- 2007-12-11 EP EP07855065.4A patent/EP2101777B1/fr not_active Revoked
- 2007-12-11 SI SI200731668T patent/SI2101777T1/sl unknown
- 2007-12-11 HU HUE07855065A patent/HUE025355T2/en unknown
2010
- 2010-02-17 US US12/706,818 patent/US20100152217A1/en not_active Abandoned
2011
- 2011-06-16 US US13/162,137 patent/US8377933B2/en active Active
2012
- 2012-12-21 US US13/723,758 patent/US20130116257A1/en not_active Abandoned
2014
- 2014-02-17 US US14/182,208 patent/US9474752B2/en active Active
2015
- 2015-04-24 US US14/695,775 patent/US9504685B2/en active Active
2016
- 2016-05-20 LU LU93081C patent/LU93081I2/fr unknown
- 2016-05-20 CY CY2016017C patent/CY2016017I2/el unknown
- 2016-05-20 HU HUS1600027C patent/HUS1600027I1/hu unknown
- 2016-06-06 HK HK16106422.7A patent/HK1218393A1/en unknown
- 2016-11-23 US US15/360,304 patent/US9993475B2/en active Active

Also Published As

Publication number	Publication date
AU2007333115A1 (en)	2008-06-19
CY2016017I1 (el)	2016-10-05
PT2101777E (pt)	2015-09-18
EP2101777B1 (fr)	2015-05-20
JP2010512414A (ja)	2010-04-22
CA2669536C (fr)	2016-05-31
US8377933B2 (en)	2013-02-19
US20140296244A1 (en)	2014-10-02
WO2008073928A1 (fr)	2008-06-19
US9474752B2 (en)	2016-10-25
ES2544724T3 (es)	2015-09-03
EP2101777A1 (fr)	2009-09-23
DK2101777T3 (en)	2015-08-17
HUS1600027I1 (hu)	2016-06-28
PL2101777T3 (pl)	2015-10-30
US20100152217A1 (en)	2010-06-17
SI2101777T1 (sl)	2015-08-31
US20110245253A1 (en)	2011-10-06
US9993475B2 (en)	2018-06-12
US9504685B2 (en)	2016-11-29
US20150224100A1 (en)	2015-08-13
EP2952193A1 (fr)	2015-12-09
HK1218393A1 (en)	2017-02-17
US20130116257A1 (en)	2013-05-09
HUE025355T2 (en)	2016-02-29
AU2007333115B2 (en)	2013-01-10
US20080139593A1 (en)	2008-06-12
US20170136016A1 (en)	2017-05-18
CA2669536A1 (fr)	2008-06-19
CY2016017I2 (el)	2016-10-05

Publication	Publication Date	Title
PT2029145T (pt)	2017-04-24	Compostos pirrolopirimidina e suas utilizações
BRPI0810814A2 (pt)	2014-10-29	Formas sólidas de dosagem incluindo tadalafil
EP2021682A4 (fr)	2013-03-13	Baladeuse
EP1985232A4 (fr)	2011-06-08	Électrocardiographe portable
DE602007008629D1 (de)	2010-10-07	Reißverschluss
BRPI0822129A2 (pt)	2015-06-23	Inibidores de aldh-2c no tratamento de vício.
EP1959029A4 (fr)	2013-07-17	Complexe de palladium et solution de traitement fournissant un catalyseur l utilisant
EP1985231A4 (fr)	2009-04-08	Electrocardiographe portable
DE602006011371D1 (de)	2010-02-04	Infrarot-eindringdetektionseinrichtung
FIU20060412U0 (fi)	2006-10-04	Suojaliivi
DK2001499T3 (da)	2013-09-08	Anvendelse af TGS-6 til behandling af osteoporose
FR2915997B1 (fr)	2009-07-03	Traitement anti-graffitis.
BRPI0914337A2 (pt)	2015-10-20	produto de limpeza enrolado portátil
BRPI0719997A2 (pt)	2014-03-18	Uso de epotilonas no tratamento de osteoporose e doenças relacionadas
TWI318128B (en)	2009-12-11	Portable water cleaner
IT1391202B1 (it)	2011-11-18	Esca rodenticida e suo uso.
FR2901326B1 (fr)	2015-09-04	Appareil de pompage roulant.
DE602006019048D1 (de)	2011-02-03	EDDH enthaltende Entzunderungslösungen
FR2904208B1 (fr)	2012-06-08	Baignoire portable
FR2899083B1 (fr)	2008-05-02	Grille-pain
FR2903669B3 (fr)	2008-06-20	02isse demontable.
ES1067241Y (es)	2008-08-01	Barbacoa portatil desarmable
DE102009022853A8 (de)	2010-04-15	Personen-Transportvorrichtung
ITMI20060730A1 (it)	2007-10-13	Friggitrice
EE00608U1 (et)	2006-07-17	Dokumendisahtel